الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 100 |  |  |
| | | from | 100 | | |
Abstract
Aim of the work:
The aim of this study is to evaluate young, eumenorrheic, healthy women sexuality after long therapy with hormonal contraceptives provided that normal male sexuality.
Patients and Methods:
Patients in this study are those who are attending the family planning clinic in Minya University Hospital, Minya
insurance hospital and Minya general hospital in the duration from October 2017 Until March 2018.
All included participants were invited to attend a personal interview done by the female investigator. The structured interviews were based to answer, in paper and-pencil format, the19-item FSFI questionnaire (Pontiroli et al.,2013) which was translated into Arabic and tested for validity and reproducibility (Anis et al.,2011). The interviews were normally completed in privacy; interviewer explained items and assisted participants in completing the questionnaire, when necessary. FSFI questionnaire assesses sexual functioning of women in six separate domains (desire, arousal, lubrication, orgasm, satisfaction, pain) in the following manner: 1st and 2nd for assessing desire; 3rd to 6th for assessing arousal; 7th to 10th for assessing lubrication; 11th to 13th for assessing orgasm; 14th to 16th for assessing satisfaction; and 17th to 19th for assessing pain. The Arabic version of FSFI is listed in the appendix.
Total scale score can be computed according to a simple scoring algorithm shown in the following (table 5). FSFI total score of ≤ 27.62 was considered diagnostic of FSD (Hassanin et al., 2018). According to a local figure FSFI total score of ≤ 28.1 was considered diagnostic of FSD (Anis et al., 2011).
Results:
In this study, The highest percentage used microcept (32%) Women used levenor (30%), women used depoprovera (20%) and implanone users represented the lowest percentage (18%) where the microcept represented the highest use and the implanone represented the lowest use in this study.In this study, oral tablets, micorcept (combined oestrogen and progesterone) did not have much negative impact on the female sexual function.
Unlikely, Depoprovera had the major negative effect on female sexual function.
Progestin containing pills (levonor) and implanone had negative effect on female sexual function but less than that of deprovera.